Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue.
作者信息
Lewis Basil S
机构信息
Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Efron Street, Haifa 3525433, Israel.
出版信息
Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):1-2. doi: 10.1093/ehjcvp/pvae099.
Abstract
摘要
相似文献
1
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue.心血管疾病与心血管药物治疗：挑战仍在，研究不止。
Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):1-2. doi: 10.1093/ehjcvp/pvae099.
2
Characteristics of length of stay and cardiovascular pharmacotherapy advice among chronic obstructive pulmonary disease patients.慢性阻塞性肺疾病患者的住院时间特征和心血管药物治疗建议。
Sci Prog. 2021 Oct;104(4):368504211066003. doi: 10.1177/00368504211066003.
3
The Use of eHealth for Pharmacotherapy Management With Patients With Respiratory Disease, Cardiovascular Disease, or Diabetes: Scoping Review.电子健康在呼吸疾病、心血管疾病或糖尿病患者药物治疗管理中的应用：范围综述。
J Med Internet Res. 2023 Sep 26;25:e42474. doi: 10.2196/42474.
4
Absolute cardiovascular disease risk score and pharmacotherapy at the time of admission in patients presenting with acute coronary syndrome due to coronary artery disease in a single Australian tertiary centre: a cross-sectional study.澳大利亚一家三级中心因冠状动脉疾病导致急性冠状动脉综合征患者入院时的绝对心血管疾病风险评分及药物治疗：一项横断面研究。
BMJ Open. 2021 Feb 8;11(2):e038868. doi: 10.1136/bmjopen-2020-038868.
5
Evaluation of Cardiovascular Pharmacotherapy Guideline Adherence and Risk Factor Control in Portuguese Community Pharmacy Patients.评估葡萄牙社区药房患者心血管药物治疗指南依从性和危险因素控制情况。
Int J Environ Res Public Health. 2022 May 19;19(10):6170. doi: 10.3390/ijerph19106170.
6
Methodological issues in pharmacotherapy research in older adults.老年人群药物治疗研究中的方法学问题。
Am J Geriatr Pharmacother. 2011 Jun;9(3):173-89. doi: 10.1016/j.amjopharm.2011.04.008.
7
[Cardiovascular pharmacotherapy in old age].[老年心血管药物治疗]
Herz. 2023 Aug;48(4):325-336. doi: 10.1007/s00059-023-05191-5. Epub 2023 Jun 12.
8
Global Trends in the Use of Pharmacotherapy for the Treatment of Bipolar Disorder.双相情感障碍药物治疗的全球使用趋势
Curr Psychiatry Rep. 2025 May;27(5):239-247. doi: 10.1007/s11920-025-01606-8. Epub 2025 Mar 27.
9
A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy.肥胖药物治疗时代的间歇性禁食与心血管风险展望
Front Nutr. 2025 Jan 17;12:1524125. doi: 10.3389/fnut.2025.1524125. eCollection 2025.
10
Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice.在学术性预防心脏病学实践中，基于新证据的心血管适应症进行药物治疗的真实世界应用情况。
Am J Prev Cardiol. 2021 Jan 5;5:100144. doi: 10.1016/j.ajpc.2020.100144. eCollection 2021 Mar.
引用本文的文献
1
Characteristics and Related Factors of Chinese Herbal Medicine Use in Middle-Aged and Older Patients with Cardiovascular Disease in China: A Cross-Sectional Study.中国心血管疾病中老年患者使用中草药的特征及相关因素：一项横断面研究
Patient Prefer Adherence. 2025 Aug 25;19:2623-2633. doi: 10.2147/PPA.S538773. eCollection 2025.
2
Early-life smoking, cardiovascular disease risk, and the mediating role of DNA methylation biomarkers of aging.早年吸烟、心血管疾病风险以及衰老的DNA甲基化生物标志物的中介作用。
J Transl Med. 2025 Apr 29;23(1):484. doi: 10.1186/s12967-025-06492-5.
本文引用的文献
1
Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis.抗血栓治疗与体重：欧洲心脏病学会心血管药物治疗工作组和欧洲心脏病学会血栓工作组的临床共识声明
Eur Heart J Cardiovasc Pharmacother. 2024 Nov 6;10(7):614-645. doi: 10.1093/ehjcvp/pvae064.
2
Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial.基于急性冠状动脉综合征亚型和高出血风险的急性冠状动脉综合征患者行经皮冠状动脉介入治疗时的阿司匹林-free 策略：STOPDAPT-3 试验。
Eur Heart J Cardiovasc Pharmacother. 2024 Aug 14;10(5):374-390. doi: 10.1093/ehjcvp/pvae009.
3
An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.阿司匹林免与双联抗血小板治疗用于冠状动脉支架置入术的比较：STOPDAPT-3 随机试验。
Circulation. 2024 Feb 20;149(8):585-600. doi: 10.1161/CIRCULATIONAHA.123.066720. Epub 2023 Nov 23.
4
A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies.一种新型小容量呋塞米皮下给药制剂，通过腹部贴片输注装置在心力衰竭患者中的应用：两项 I 期研究结果。
Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):35-44. doi: 10.1093/ehjcvp/pvad073.
5
2023 ESC Guidelines on ACS: what is new in antithrombotic therapy?2023年欧洲心脏病学会急性冠状动脉综合征指南：抗栓治疗有哪些新内容？
Eur Heart J Cardiovasc Pharmacother. 2023 Nov 2;9(7):595-596. doi: 10.1093/ehjcvp/pvad065.
6
External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis.PCI 患者中 PRECISE-DAPT 评分的外部效度：一项系统评价与荟萃分析
Eur Heart J Cardiovasc Pharmacother. 2023 Dec 14;9(8):709-721. doi: 10.1093/ehjcvp/pvad063.
7
2023 ESC Guidelines for the management of acute coronary syndromes.2023年欧洲心脏病学会急性冠状动脉综合征管理指南。
Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.
8
Bleeding risk and P2Y12 inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-centre cohort study.所有接受经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者的出血风险和 P2Y12 抑制剂：一项单中心队列研究。
Eur Heart J Cardiovasc Pharmacother. 2023 Nov 2;9(7):617-626. doi: 10.1093/ehjcvp/pvad048.
9
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.非奈利酮与慢性肾病和 2 型糖尿病患者的死亡率：FIDELITY 分析。
Eur Heart J Cardiovasc Pharmacother. 2023 Feb 2;9(2):183-191. doi: 10.1093/ehjcvp/pvad001.
10
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis.复杂经皮冠状动脉介入治疗后P2Y12抑制剂单药治疗的疗效与安全性：一项协作性系统评价与荟萃分析
Eur Heart J Cardiovasc Pharmacother. 2023 Apr 10;9(3):240-250. doi: 10.1093/ehjcvp/pvac071.
Zotero 插件